Core Scientific (CORZ) Equity Average (2021 - 2026)

Core Scientific (CORZ) has 6 years of Equity Average data on file, last reported at -$1.1 billion in Q1 2026.

• Quarterly Equity Average fell 81.2% year-over-year to -$1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 billion (down 81.2% YoY) and the FY2025 annual result came in at -$952.9 million, down 23.75% from the prior year.
• Equity Average slipped to -$1.1 billion in Q1 2026 per CORZ's latest filing, from -$1.1 billion in the prior quarter.
• The five-year high for Equity Average was $1.2 billion in Q1 2022, with the low at -$1.2 billion in Q3 2025.
• Average Equity Average over 5 years is -$445.1 million, with a median of -$507.8 million recorded in 2023.
• Year-over-year, Equity Average soared 1224.13% in 2022 and tumbled 265.72% in 2023.
• Core Scientific's Equity Average stood at -$168.2 million in 2022, then tumbled by 202.0% to -$507.8 million in 2023, then plunged by 74.24% to -$884.9 million in 2024, then declined by 25.18% to -$1.1 billion in 2025, then dropped by 2.39% to -$1.1 billion in 2026.
• Business Quant data shows CORZ's Equity Average at -$1.1 billion in Q1 2026, -$1.1 billion in Q4 2025, and -$1.2 billion in Q3 2025.